# Phase Ib/IIa Trial With AC01 in Patients With HFrEF

> **NCT05642507** · PHASE1,PHASE2 · COMPLETED · sponsor: **AnaCardio AB** · enrollment: 58 (actual)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** AC01
- **DRUG:** Placebo Minitablets

## Key facts

- **NCT ID:** NCT05642507
- **Lead sponsor:** AnaCardio AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-23
- **Primary completion:** 2025-10-27
- **Final completion:** 2025-10-27
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05642507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05642507, "Phase Ib/IIa Trial With AC01 in Patients With HFrEF". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT05642507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*